Sulfonylurea compounds as inhibitors of interleukin-1 activity
US11560391B2 · kind B2 · utility
0Cited by
3References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 15, 2021 |
| Grant date | Jan 24, 2023 |
| Priority date | — |
| Expiry date | Jan 15, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.